Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent~* HCV RNA ≥ 10\^4 IU/mL at screening~* HCV genotype 1, 2, 4, 5, 6, or indeterminate assessed at screening by the central laboratory~* Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy~* Classification as treatment naive or treatment experienced~* Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception~Exclusion Criteria:~* Current or prior history of clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with treatment, assessment, or compliance with the protocol; individuals currently under evaluation for a potentially clinically-significant illness (other than HCV) are also excluded.~* Screening ECG with clinically significant abnormalities~* Laboratory results outside of acceptable ranges at Screening~* Prior exposure to SOF or other nucleotide analogue HCV NS5B inhibitor or any HCV NS5A inhibitor~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): SOF/VEL for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): SOF/VEL placebo for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).